Physicians' Academy for Cardiovascular Education

ACS

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD

Sex-related differences in ACS patients

5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Reduced long-term CV death and MI with complete multivessel revascularization in STEMI

3' education - Sep. 25, 2019 - Paris, France - Prof. Shamir Mehta

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

No beneficial effects of oxygen use in subjects with a heart attack

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Ralph Stewart, New Zealand

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens

Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results

3' education - Sep. 1, 2019 - Paris, France - Prof. Stefanie Schüpke

Major benefits with implementation of rapid rule-out pathway for MI

3' education - Sep. 1, 2019 - Prof. Nicholas Mills

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

10' education - Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby

Cardiovascular Inflammation and Immunity in Atherosclerosis:

10' education - June 7, 2015 - Amsterdam
##SCROLLER_ITEMS_FULL_TITLE##

HDL mimetics: New promise in ACS?

3' education - Sep. 15, 2014 - Barcelona 2014 - Prof Kausik Ray MD

Oral load of colchicine prior to PCI prevents a rise of inflammatory biomarkers in acute injury

News - Nov. 18, 2019

AHA 2019 Pre-procedural administration of colchicine vs. placebo did not reduce PCI-related myocardial injury or MACE at 30 days, but attenuated increase in IL-6 and hsCRP at 24 hours post-PCI.

Identification of parameters associated with plaque erosion in STEMI and NSTE-ACS

Literature - Oct. 30, 2019 - Yamamoto E et al., - J Am Heart Assoc. 2019

Exploratory analysis identifies predictors of plaque erosion in patients with ACS who underwent OCT imaging. A combination of non-traditional risk factors can increase the probability of erosion to up to 73%.

P2Y12i monotherapy reduces ischemic outcomes in patients undergoing multivessel PCI

Literature - Oct. 28, 2019 - Takahashi K, et al. - J Am Coll Cardiol 2019

A post-hoc analysis of the GLOBAL LEADERS trial in patient undergoing multivessel PCI showed that ticagrelor monotherapy reduced all-cause death or MI, without any difference in bleeding compared to standard DAPT regimen.

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD
Camilla Bang shares preliminary results of her study on applying high-sensitive troponin results measured 30 minutes after admission to rule in or rule out acute MI in individuals with chest pain.

CSI Paris Camilla Bang shares preliminary results of her study on applying high-sensitive troponin results measured 30 minutes after admission to rule in or rule out acute MI in individuals with chest pain.

Sex-related differences in ACS patients

5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD
Sanne Peters and Tamar de Vries talk about differences in impact of CV risk factors in women and men, and they highlight the need for awareness of sex-related differences in treatment effects.

CSI Paris Sanne Peters and Tamar de Vries talk about differences in impact of CV risk factors in women and men, and they highlight the need for awareness of sex-related differences in treatment effects.

Ischemic outcomes with antithrombotic regimes in AF patients with ACS or undergoing PCI

Literature - Oct. 14, 2019 - Potpara TS, et al. - Europace 2019

A meta-analysis of RE-DUAL PCI, PIONEER AF-PCI and AUGUSTUS compared NOAC- and VKA-based regimens and antithrombotic therapies with and without aspirin for ischemic outcomes and CV and total mortality.

In-hospital initiation of PCSK9 inhibitor after ACS helps achieve LDL-c target at 8 weeks

Literature - Oct. 3, 2019 - Koskinas KC et al. - J Am Coll Cardiol. 2019

Starting evolocumab treatment on top of high-intensity statin, in the hospital soon after ACS, safely and effectively lowers LDL-c to below guideline-recommended levels for almost all.

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD
As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

Reduced long-term CV death and MI with complete multivessel revascularization in STEMI

3' education - Sep. 25, 2019 - Paris, France - Prof. Shamir Mehta
Based on data of the COMPLETE trial, prof. Mehta answers the questions whether routine complete revascularization vs. culprit lesion only PCI can change cardiac outcomes and disease course, and whether it should become standard practice for patients with STEMI.

ESC 2019 Based on data of the COMPLETE trial, prof. Mehta answers the questions whether routine complete revascularization vs. culprit lesion only PCI can change cardiac outcomes and disease course, and whether it should become standard practice for patients with STEMI.

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD
Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.

Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach
Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.

ESC 2019 Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.

No beneficial effects of oxygen use in subjects with a heart attack

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Ralph Stewart, New Zealand
Prof. Stewart investigated two protocols for oxygen administration in 40,000 patients with ischemic symptoms in New-Zealand. In most, oxygen gives no advantages and no disadvantages, but a subgroup may benefit from oxygen.

ESC 2019 Prof. Stewart investigated two protocols for oxygen administration in 40,000 patients with ischemic symptoms in New-Zealand. In most, oxygen gives no advantages and no disadvantages, but a subgroup may benefit from oxygen.